Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Inclusion Criteria:

• Type 2 diabetes mellitus
• Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
• HbA1c for diet treated subjects 6.5-12%, both inclusive
• HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%
• Body mass index (BMI) at least 27 kg/m^2
• Euthyroid subjects
• Fasting blood glucose 7-14 mmol/l

Exclusion Criteria:

• Impaired liver function
• Impaired renal function
• Cardiac problems
• Uncontrolled treated/untreated hypertension
• Recurrent severe hypoglycaemia as judged by the Investigator
• Known or suspected allergy to trial product or related products
• Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed